A single-center experience in 20 patients with infantile malignant osteopetrosis

American Journal of Hematology

Volumn 84, Issue 8, 2009, Pages 473-479

  Mazzolari, Evelina ^a   Forino, Concetta ^a   Razza, Alessia ^a   Porta, Fulvio ^a   Villa, Anna ^b,c   Notarangelo, Luigi Daniele ^d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIBIOTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN; LEUKOCYTE ANTIBODY; LEUKOCYTE FUNCTIONAL ANTIGEN 1 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD2; THIOTEPA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ACUTE GRAFT VERSUS HOST DISEASE; ALBERS SCHOENBERG DISEASE; ARTICLE; CELL FUNCTION; CICN7 GENE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG BLOOD LEVEL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; FRAMESHIFT MUTATION; GENE; GENE DELETION; GENE INSERTION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFANT; INFANT DISEASE; INFANTILE MALIGNANT OSTEOPETROSIS; LABORATORY TEST; MALE; MUTATIONAL ANALYSIS; MYELOABLATIVE CONDITIONING; NEUROLOGIC DISEASE; OSTEOCLAST; OSTM1 GENE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SPLICING DEFECT; SURVIVAL RATE; SURVIVAL TIME; TCIRG1 GENE; TNFRSF11A GENE; WHOLE BODY RADIATION;

AGAMMAGLOBULINEMIA; CHLORIDE CHANNELS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENETIC DISEASES, INBORN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; MALE; MEMBRANE PROTEINS; OSTEOPETROSIS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; UBIQUITIN-PROTEIN LIGASES; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 67749093440     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21447     Document Type: Article

References (55)

1. Gerritsen EJ, Vossen JM, van Loo IH, et al. Autosomal recessive osteopetrosis: Variability of findings at diagnosis and during the natural course. Pediatrics 1994;93:247-253.
2. Fasth A, Porras O. Human malignant osteopetrosis: Pathophysiology, management and the role of bone marrow transplantation. Pediatr Transplant 1999;3(Suppl 1):102-107.
3. Wilson CJ, Vellodi A. Autosomal recessive osteopetrosis: Diagnosis, management and outcome. Arch Dis Child 2000;83:449-452. (Pubitemid 30828369)
4. Mohn A, Capanna R, Delli Pizzi C, et al. Autosomal malignant osteopetrosis. Minerva Pediatr 2004;56:115-118.
5. Steward CG. Neurological aspects of osteopetrosis. Neuropathol Appl Neurobiol 2003;29:87-97.
6. Walker DG. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 1975;190:784-785.
7. Walker DG. Control of bone resorption by hematopoietic tissue. The induction and reversal of congenital osteopetrosis in mice through use of bone marrow and splenic transplants. J Exp Med 1975;142:651-663.
8. Ballet JJ, Griscelli C, Coutris C, et al. Bone marrow transplantation in osteopetrosis. Lancet 1977;2:1137.
9. Coccia PF, Krivit W, Cervenka J, et al. Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med 1980;302:701-708. (Pubitemid 10132096)
10. Fischer A, Griscelli C, Friedrich W, et al. Bone-marrow transplantation for immunodeficiencies and osteopetrosis: European survey, 1968-1985. Lancet 1986;2:1080-1084.
11. Gerritsen EJ, Vossen JM, Fasth A, et al. Bone marrow transplantation for autosomal recessive osteopetrosis. J Pediatr 1994;125:896-902. (Pubitemid 24379122)
12. Driessen GJA, Gerritsen EJ, Fischer A, et al. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: An EBMT report. Bone Marrow Transplant 2003;32:657-663. (Pubitemid 37258621)
13. Key LL, Carnes D, Cole S, et al. Treatment of congenital osteopetrosis with high-dose calcitriol. N Engl J Med 1984;310:409-415. (Pubitemid 14186355)
14. Key LL Jr, Rodriguiz RM, Willi SM, et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med 1995;332:1594-1599.
15. Sobacchi C, Frattini A, Orchard P, et al. The mutational spectrum of human malignant autosomal recessive asteopetrosis. Hum Mol Genet 2001;10:1767-1773. (Pubitemid 32899094)
16. Guerrini MM, Sobacchi C, Cassani B, et al. Human osteoclast poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008;83:64-76. (Pubitemid 351916706)
17. Frattini A, Pangrazio A, Susani L, et al. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant and intermediate osteopetrosis. J Bone Miner Res 2003;18:1740-1747. (Pubitemid 37322549)
18. Chalhoub N, Benachenhou N, Rajapurohitam V, et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med 2003;9:399-406. (Pubitemid 36460073)
19. Ramirez A, Faupel J, Goebel I, et al. Identification of a novel mutation in the coding region of the grey-lethal gene OSTM1 in human malignant infantile osteopetrosis. Hum Mut 2004;23:471-476. (Pubitemid 38569220)
20. Frattini A, Orchard PJ, Sobacchi C, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 2000;25:343-346. (Pubitemid 30437326)
21. Kornak U, Kasper D, Bösl MR, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001;104:205-215.
22. Quarello P, Forni M, Barberis L, et al. Severe malignant osteopetrosis caused by a GL gene mutation. J Bone Miner Res 2004;19:1194-1199.
23. Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007;39:960-962. (Pubitemid 47185178)
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
25. Van Wesenbeeck L, Van Hul W. Lessons from osteopetrotic mutations in animals: Impact on our current understanding of osteoclast biology. Crit Rev Eukaryot Gene Expr 2005;15:133-162. (Pubitemid 41277408)
26. Segovia-Silvestre T, Neutzsky-Wulff AV, Sorensen MG, et al. Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet 2009;124:561-577.
27. Tolar J, Teitelbaum SL, Orchard PJ. Mechanisms of disease. Osteopetrosis. N Engl J Med 2004;351:2839-2849.
28. Balemans W, Van Wesenbeeck L, Van Hul W. A clinical and molecular overview of the human osteopetrosis. Calcif Tissue Int 2005;77:263-274. (Pubitemid 41704904)
29. Askmyr MK, Fasth A, Richter J. Towards a better understanding and new therapeutics of osteopetrosis. Br J Haematol 2008;140:597-609. (Pubitemid 351300923)
30. Pangrazio A, Poliani PL, Megarbane A, et al. Mutations in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteopetrosis with neural involvement. J Bone Miner Res 2006;21:1098-1105. (Pubitemid 43962838)
31. Maranda B, Chabot G, Décarie JC, et al. Clinical and cellular manifestations of OSTM1-related infantile osteopetrosis. J Bone Miner Res 2008;23:296-300. (Pubitemid 351160044)
32. Castellano Chiodo D, DiRocco M, Gandolfo C, et al. Neuroimaging findings in malignant infantile osteopetrosis due to OSTM1 mutations. Neuropediatrics 2007;38:154-156. (Pubitemid 350195634)
33. Kasper D, Planells-Cases R, Fuhrmann JC, et al. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J 2005;24:1079-1091. (Pubitemid 40470155)
34. Jentsch TJ. Chloride and the endosomal-lysosomal pathway: Emerging roles of ClC chloride transporters. J Physiol 2007;578:633-640.
35. Lange PF, Wartosch L, Jentsch TJ, Fuhrmann JC. ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 2006;440:220-223. (Pubitemid 43372100)
36. Feigin ME, Malbon CC. OSTM1 regulates beta-catenin/Lef1 interaction and is required for Wnt/beta-catenin signaling. Cell Signal 2008;20:949-957.
37. Prinetti A, Rocchetta F, Costantino E, et al. 2008. Brain lipid composition in grey-lethal mutant mouse characterized by severe malignant osteopetrosis. Glycoconj J.10.1007/s10719-008-9179-9188
38. Steward CG, Pellier I, Mahajan A, et al. Severe pulmonary hypertension: A frequent complication of stem cell transplantation for malignant infantile osteopetrosis. J Haematol 2004;124:63-71. (Pubitemid 38021624)
39. Kasow KA, Bonfim C, Asch J, et al. Malignant infantile osteopetrosis and primary pulmonary hypertension: A new combination? Pediatr Blood Cancer 2004;42:190-194.
40. Simonet WS, Lacey DL, Dunstan, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
41. Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990;345:442-444. (Pubitemid 120014957)
42. Lawrie A, Waterman E, Southwood M, et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol 2008;172:256-264. (Pubitemid 351186386)
43. Blin-Wakkach C, Wakkach A, Sexton PM, et al. Hematological defects in the oc/oc mouse, a model of infantile malignant osteopetrosis. Leukemia 2004;18:1505-1511. (Pubitemid 39264073)
44. Utku N, Heinemann T, Tullius SG, et al. Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity 1998;9:509-518. (Pubitemid 28499202)
45. Heinemann T, Bulwin GC, Randall J, et al. Genomic organization of the gene coding for TIRC7, a novel membrane protein essential for T cell activation. Genomics 1999;57:398-406. (Pubitemid 29239227)
46. Utku N, Boerner A, Tomschegg A. TIRC7 deficiency causes in vitro and in vivo augmentation of T and B cell activation and cytokine response. J Immunol 2004;173:2342-2352.
47. Blin-Wakkach C, Wakkach A, Sexton PM, et al. Hematological defects in the oc/oc mouse, a model of infantile malignant osteopetrosis. Leukemia 2004;18:1505-1511. (Pubitemid 39264073)
48. Johansson M, Jansson L, Ehinger M, et al. Neonatal hematopoietic stem cell transplantation cures oc/oc mice from osteopetrosis. Exp Hematol 2006;34:242-249. (Pubitemid 43184329)
49. Rossi SW, Kim MY, Leibbrandt A, et al. RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med 2007;204:1267-1272.
50. Sun-Wada GH, Toyomura T, Murata Y, et al. The a3 isoform of V-ATPase regulates insulin secretion from pancreatic beta-cells. J Cell Sci 2006;119:4531-4540. (Pubitemid 44830652)
51. Sun-Wada GH, Tabata H, Kawamura N, et al. Differential expression of a subunit isoforms of the vacuolar-type proton pump ATPase in mouse endocrine tissues. Cell Tissue Res 2007;329:239-248. (Pubitemid 47020522)
52. Corbacioglu S, Honig M, Stohr S, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant 2006;38:547-553. (Pubitemid 44509547)
53. Frattini A, Blair HC, Sacco MG, et al. Rescue of ATPa3-deficient murine malignant osteopetrosis by hematopoietic stem cell transplantation in utero. Proc Natl Acad Sci USA 2005;102:14629-14634. (Pubitemid 41457107)
54. Tondelli B, Blair HC, Guerrini M, et al. Fetal liver cells transplanted in utero rescue the osteopetrotic phenotype in the oc/oc mouse. Am J Pathol 2009;174:727-735.
55. Johansson MK, de Vries TJ, Schoenmaker T, et al. Hematopoietic stem cell targeted neonatal gene therapy reverses lethally progressive osteopetrosis in oc/oc mice. Blood 2007;15:5178-5185. (Pubitemid 46890534)